Sheela Rao

2 weeks ago | ajmc.com | Brooke McCormick |Sheela Rao

On May 15, the FDA approved retifanlimab-dlwr (Zynyz; Incyte) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal. It was also approved as a monotherapy for those whose disease has progressed or who are intolerant to platinum-based chemotherapy.